Targets › HSD11B1
3 programs from 3 companies in 8 trials: 4 Phase 1, 2 Phase 3, 2 Phase 2; Oncology, Psychiatry, Genitourinary; next expected readout Nov 2027.
Controls the reversible conversion of biologically active glucocorticoids such as cortisone to cortisol, and 11-dehydrocorticosterone to corticosterone in the presence of NADP(H). Participates in the corticosteroid receptor-mediated anti-inflammatory response, as well as metabolic and homeostatic processes. (UniProt, P28845)
Open in Phaseline: the race on HSD11B1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Merck & Co. (MSD) | Opevesostat (MK-5684) 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor blocking steroid hormone synt | HSD11B1, AR | Phase 3 | Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostate Cancer Metastatic; Malignant Neoplasm; Prostatic Neoplasms, Castration-Resistant … | Nov 2027 |
| Sparrow Pharmaceuticals | clofutriben 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1) inhibitor | HSD11B1 | Phase 2 | Type 2 Diabetes; Moderate Renal Impairment | Dec 2027 |
| Philipps University Marburg | Enoxolone 11β-hydroxysteroid dehydrogenase inhibitor | HSD11B1 | Phase 1 | Unipolar Depression | – |
Metastatic Castration-resistant Prostate Cancer (mCRPC) (1) Prostate Cancer Metastatic (1) Malignant Neoplasm (1) Prostatic Neoplasms, Castration-Resistant (1) Castration-Resistant Prostatic Cancer (1) Unipolar Depression (1) Type 2 Diabetes (1) Moderate Renal Impairment (1)
small molecule (3)
Merck & Co. (MSD) (1) Philipps University Marburg (1) Sparrow Pharmaceuticals (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.